In the past week, TMDX stock has gone down by -4.81%, with a monthly decline of -2.21% and a quarterly plunge of -52.97%. The volatility ratio for the week is 6.71%, and the volatility levels for the last 30 days are 6.49% for Transmedics Group Inc The simple moving average for the past 20 days is -7.21% for TMDX’s stock, with a -50.24% simple moving average for the past 200 days.
Is It Worth Investing in Transmedics Group Inc (NASDAQ: TMDX) Right Now?
The price-to-earnings ratio for Transmedics Group Inc (NASDAQ: TMDX) is above average at 63.78x, Company’s 36-month beta value is 2.09.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for TMDX is 32.43M, and currently, short sellers hold a 28.23% ratio of that floaft. The average trading volume of TMDX on January 22, 2025 was 2.30M shares.
TMDX) stock’s latest price update
Transmedics Group Inc (NASDAQ: TMDX)’s stock price has soared by 4.94 in relation to previous closing price of 56.73. Nevertheless, the company has seen a loss of -4.81% in its stock price over the last five trading days. accessnewswire.com reported 2025-01-22 that LOS ANGELES, CA / ACCESS Newswire / January 22, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TransMedics Group, Inc. (“TransMedics” or “the Company”) (NASDAQ:TMDX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Analysts’ Opinion of TMDX
Many brokerage firms have already submitted their reports for TMDX stocks, with JP Morgan repeating the rating for TMDX by listing it as a “Neutral.” The predicted price for TMDX in the upcoming period, according to JP Morgan is $75 based on the research report published on December 17, 2024 of the previous year 2024.
Oppenheimer gave a rating of “Outperform” to TMDX, setting the target price at $125 in the report published on October 29th of the previous year.
TMDX Trading at -16.78% from the 50-Day Moving Average
After a stumble in the market that brought TMDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.43% of loss for the given period.
Volatility was left at 6.49%, however, over the last 30 days, the volatility rate increased by 6.71%, as shares sank -2.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.70% lower at present.
During the last 5 trading sessions, TMDX fell by -5.70%, which changed the moving average for the period of 200-days by -23.61% in comparison to the 20-day moving average, which settled at $64.14. In addition, Transmedics Group Inc saw -4.52% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TMDX starting from Khayal Tamer I, who sale 1,083 shares at the price of $80.05 back on Jan 07 ’25. After this action, Khayal Tamer I now owns 20,843 shares of Transmedics Group Inc, valued at $86,694 using the latest closing price.
Khayal Tamer I, the Chief Commercial Officer of Transmedics Group Inc, sale 1,084 shares at $86.40 during a trade that took place back on Dec 02 ’24, which means that Khayal Tamer I is holding 20,843 shares at $93,658 based on the most recent closing price.
Stock Fundamentals for TMDX
Current profitability levels for the company are sitting at:
- 0.08 for the present operating margin
- 0.59 for the gross margin
The net margin for Transmedics Group Inc stands at 0.08. The total capital return value is set at 0.04. Equity return is now at value 19.41, with 4.43 for asset returns.
Based on Transmedics Group Inc (TMDX), the company’s capital structure generated 0.71 points at debt to capital in total, while cash flow to debt ratio is standing at 0.07. The debt to equity ratio resting at 2.47. The interest coverage ratio of the stock is 2.91.
Currently, EBITDA for the company is -7.6 million with net debt to EBITDA at 3.23. When we switch over and look at the enterprise to sales, we see a ratio of 5.49. The receivables turnover for the company is 4.45for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.20.
Conclusion
In a nutshell, Transmedics Group Inc (TMDX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
